Aim: The aim of this study was to evaluate the correlation between hepatitis B core-related antigen (HBcrAg) and hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) levels, and to investigate HBcrAg kinetics during nucleos(t)ide analogue (NA) or pegylated-interferon (PEG-IFN)-α treatment in a cohort of chronic hepatitis B (CHB) genotype D patients.
INTRODUCTION

H EPATITIS B VIRUS (HBV)
is the second greatest cause of chronic viral hepatitis worldwide. Despite decades of vaccination, the estimated number of chronic HBV surface antigen (HBsAg) carriers in the world is approximately 350-400 million. 1 In developed countries, chronic hepatitis B (CHB) is mainly the result of an acute, unresolved infection that, over time, may lead to cirrhosis and its complications such as liver failure and hepatocellular carcinoma (HCC). 2 Currently, there are several drugs approved for CHB treatment including recombinant interferon (IFN), an immune-modulatory agent, and nucleos (t)ide analogues (NA), oral drugs that directly inhibit viral replication. 3 The major goal in CHB treatment is to prevent disease progression suppressing viral replication and maintaining a virological remission. Then, inflammation reduction prevents fibrosis progression, decreasing the risk of cirrhosis and theoretically of HCC. The final endpoint is HBsAg loss and eventually seroconversion to anti-HBs. 4 Several reliable serological and molecular parameters are available to clinicians for optimal management of CHB infected patients. According to international guidelines, indication for treatment initiation depends on well-known parameters such as HBV DNA levels, alanine aminotransferase (ALT), and severity of liver disease. 1, 5, 6 In addition, HBV DNA levels and quantitative HBsAg have gained increasing attention as potential predictors of hepatitis reactivation, disease progression, and HCC development. [7] [8] [9] In addition to conventional serological markers for hepatitis B, a novel 22-kDa precore/core protein (p22cr), named hepatitis B core-related antigen (HBcrAg) has been recently described as the main capsid protein in viral DNAnegative Dane particles. In serum, p22cr-containing particles are more abundant than those containing hepatitis B core antigen (HBcAg). In addition, because the precore non-sense mutation abolishes precore protein expression, the precore mutation must influence the HBcAg/HBcrAg ratios and the ratios of particle-forming p22cr to soluble hepatitis B e antigen (HBeAg) ratios in serum. 10 Furthermore, due to its correlation with intrahepatic covalently closed circular DNA (cccDNA) levels, HBcrAg quantitation has been proposed as a useful tool for monitoring intrahepatic HBV status. 11, 12 Low HBcrAg levels were associated with favorable entecavir (ETV) treatment outcome and response to NA/IFN-α sequential therapy, and with lower risk of hepatitis reactivation following discontinuation of lamivudine (LAM). [13] [14] [15] Conversely, elevated serum HBcrAg levels have been associated with higher risk of either HCC development or HCC recurrence after curative therapy. 16, 17 In addition, it has been shown that the different phases of CHB infection can be distinguished according to HBcrAg serum levels. 18, 19 As current available data on HBcrAg are mainly limited to Asian CHB patients infected with HBV genotypes B and C, the aim of the present study is to evaluate HBcrAg kinetics during NA and pegylated (PEG)-IFN-α treatment and its correlation with HBV DNA and HBsAg levels in an Italian cohort of HBeAg-negative patients chronically infected with HBV genotype D. patients received LAM 100 mg/day, 5 received LAM 100 mg/day + adefovir dipivoxil 10 mg/day, 11 received ETV 0.5 mg/day, and 2 received tenofovir 300 mg/day. Patients treated with PEG-IFN-α received a dose of 180 μg/week for an 18-month course of treatment. Virological and biochemical response were defined as sustained decrease of HBV DNA to <20 IU/mL and sustained ALT normalization (<40 IU/L), respectively. A pre-treatment serum sample was available for all included patients. Sixteen patients included in the study were treatment naïve, and 12 were treatment experienced.
METHODS
All patients gave their written informed consent prior to recruitment. The study protocol conformed to the principles of the Declaration of Helsinki and it was approved by the Institutional Ethics Committee.
Laboratory testing
The two-step fully automated chemiluminescent microparticle immunoassay ARCHITECT-QT (Abbott Diagnostics, Abbott Park, IL, USA) was used for quantitative determination of human serum HBsAg concentrations using acridium-labeled anti-HBs conjugate as previously described. 20 The assay has a dynamic range of 0.05-250.00 IU/mL with onboard dilution for results out of the range. Qualitative determination of HBeAg was carried out with the ARCHITECT HBeAg assay. Results are expressed as sample/cut-off relative light units. Specimens with sample/cut-off values <1.000 are considered non-reactive. Hepatitis B virus DNA was detected and quantified in patients' serum samples by a fully automated real-time polymerase chain reaction system, the COBAS AmpliPrep/COBAS TaqMan HBV test, version 2.0 (Roche Molecular Diagnostics, Branchburg, NJ, USA) whose detection limit is 20 IU/mL. 21 Hepatitis B virus genotypes were determined based on reverse hybridization line probe assay (INNO-LiPA HBV Genotyping; Fujirebio Europe, Gent, Belgium) designed to identify HBV genotypes A to H by detection of type-specific sequences in the HBV polymerase gene domains B and C.
Serum HBcrAg levels were determined using a chemiluminescent enzyme immunoassay kit Lumipulse G HBcrAg (Fujirebio Europe) on a fully automated system, Lumipulse G600 II analyzer (Fujirebio Europe), as previously described. 11 The assay measures HBeAg, HBcAg, and HBcrAg and the concentration is calculated by comparison with a standard curve generated using recombinant pro-HBeAg. The immunoreactivity of pro-HBeAg at 10 fg/mL is defined as 1 U/mL. The HBcrAg values are expressed as Log U/mL with an analytic measurement range between 2.0 and 7.0 Log U/mL. Repeated measures ANOVA was carried out to analyze kinetics of HBV markers. Longitudinal analysis was carried out on patients' sera at baseline and months 6, 12, 24, and 36 of NA therapy, and at baseline, months 6, 12, and 18 (end of treatment), and month 6 of post-therapy followup (FU) of PEG-IFN-α treatment. For all analyses, P < 0.05 was considered statistically significant. All statistical analyses were carried out using MedCalc software version 12.7.0.0 (MedCalc, Ostend, Belgium).
Statistical analysis
RESULTS
Patients' characteristics D EMOGRAPHIC, VIROLOGICAL, AND clinical baseline characteristics of the study cohort are reported in Table 1 . We found no significant differences between patients that underwent NA or PEG-IFN-α treatment regarding age, gender, and pretreatment levels of HBV DNA, HBsAg, HBcrAg, and ALT. The only significant difference was found in naïve/experienced ratio to previous treatment (P = 0.0084). Regarding treatment response, all patients who underwent NA treatment had a virological and biochemical sustained response, whereas among patients that underwent PEG-IFN-α, 4 patients did not respond to therapy and 4 patients relapsed within 6 months post-treatment (HBV DNA > 2000 IU/mL and ALT >40 IU/L). Baseline HBcrAg levels were significantly higher in non-responder patients compared to relapse patients (4.4 ± 2.4 Log U/mL vs. 2.4 ± 0.8 Log U/mL, respectively; P = 0.0458). No differences were found in HBV DNA (5.4 ± 1.6 Log IU/mL vs. 3.8 ± 1.8 Log IU/mL; P = 0.2375) or HBsAg (3.6 ± 0.6 Log IU/mL vs. 2.7 ± 1.0 Log IU/mL; P = 0.2099) basal levels according to treatment outcome.
Correlation analysis
The correlation between HBcrAg, HBV DNA, and/or HBsAg in the 138 serum samples of the 28 enrolled patients is depicted in Figure 1 . Overall, HBcrAg showed a moderate correlation with HBV DNA levels (r = 0.4981; 95% confidence interval [CI], 0.3599-0.6149; P < 0.0001) (Fig. 1a ) but no correlation with HBsAg (r = 0.1919; 95%CI, À0.01344-0.3817; P = 0.0669) (Fig. 1b) . A weaker correlation was observed between HBV DNA and HBsAg (r = 0.2678; 95%CI, 0.06427-0.4499; P = 0.0107) (Fig. 1c) . Next, HBcrAg concentration was correlated to HBV DNA levels according to therapy: there was a stronger correlation in patients who received PEG-IFN-α treatment than in those with NA treatment (r = 0.7865; 95%CI, 0.6292-0.8820; P < 0.0001 vs. r = 0.4960; 95%CI, 0.3281-0.6335; P < 0.0001, respectively; z-statistic 2.6661, P = 0.0077). However, in the correlation analysis between HBV DNA and HBcrAg basal values, no difference was found according to treatment group (PEG-IFN-α: r = 0.7522; 95%CI, 0.1011-0.9522; ALT, alanine aminotransferase; HBcrAg, hepatitis B core-related antigen; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; NA, nucleos(t) ide analogue; PEG-IFN-α, pegylated-interferon-α; SD, standard deviation. P = 0.0313 vs. NA, r = 0.5203; 95%CI, 0.1011-0.7826; P = 0.0187, respectively; z-statistic À0.7887, P = 0.4303).
Regarding the correlation between HBcrAg and HBsAg, no statistically significant correlation was found in patients who underwent either PEG-IFN-α or NA treatment (r = 0.2830; 95%CI, À0.1463-0.6226; P = 0.1908 vs. r = 0.1555; 95%CI, À0.0843-0.3782; P = 0.2021, respectively). In contrast, HBV DNA and HBsAg were correlated in both groups of patients without a statistically significant difference between patients treated with PEG-IFN-α and those treated with NA (r = 0.4190; 95%CI, 0.0082-0.7088; P = 0.0466 vs. r = 0.0327; 95%CI, 0.0225-0.4719; P = 0.0327, respectively; z-statistic 0.6987, P = 0.4848).
Longitudinal analysis
Kinetics of HBcrAg, HBV DNA, and HBsAg mean levels in patients treated with NA and those treated with PEG-IFN-α are depicted in Figure 2 . In serial serum samples, a significant HBcrAg reduction was observed only in patients receiving NA (P = 0.019). No significant variation was observed in PEG-IFN-treated patients (P = 0.172). A statistically significant longitudinal variation resulted for HBV DNA levels both in patients treated with NA and in those treated with PEG-IFN-α (P < 0.001 and P = 0.001, respectively). Almost no changes occurred in HBsAg kinetics in NA-treated patients or in the PEG-IFN-α group (P = 0.077 and P = 0.190, respectively). Of interest, among patients treated with NA, we observed a subgroup (n = 12) that experienced an early HBcrAg decline, reaching undetectable values between months 6 and 12 (<2 Log U/mL), whereas another group (n = 8) maintained sustained HBcrAg values at last FU (4.4 ± 0.6 Log U/mL at month 36) regardless of HBV DNA and HBsAg kinetics (Fig. 3) . Moreover, the rapid decliner group showed HBcrAg kinetics similar to HBV DNA (P = 0.243) and significantly different from HBsAg (P = 0.021). Contrarily, patients with HBcrAg-positive values at last FU showed HBcrAg kinetics significantly different from HBV DNA (P = 0.006) and similar to HBsAg (P = 0.216). Furthermore, basal HBcrAg levels in patients with early decline were significantly lower compared to patients with still detectable HBcrAg at month 36 (3.8 ± 1.7 Log U/mL vs. 5.9 ± 1.3 Log U/mL, P = 0.0109).
Based on HBcrAg and HBsAg values at therapy month 36, patients treated with NA were further classified according to the relapse risk score following NA therapy cessation proposed by the Japan Society of Hepatology (JSH) guidelines. 22, 23 All rapid decliner patients were classified into the moderate risk group (total score 1 [n = 6] or 2 [n = 6]); patients in the HBcrAg-positive group at month 36 were classified into the high risk of relapse group (total score 1 [n = 1], 3 [n = 2], or 4 [n = 5]) (P = 0.0005).
DISCUSSION
P RIMARY MARKERS FOR treatment monitoring in CHB patients include HBeAg for seroconversion of HBeAg-positive patients, ALT for biochemical response, and HBV DNA for virological response. 24 Hepatitis B surface antigen quantitation became another important marker to predict HBsAg negativization and seroconversion to anti-HBs. Several studies investigated the role of such markers in therapy outcome prediction. 25 In particular, it has been shown that in IFN-based therapy HBV DNA is not a reliable predictor of sustained response because of similar kinetics between non-responder patients and those who relapse, whereas in NA-treated patients, HBV DNA becomes rapidly undetectable without ensuring that viral replication will not reactivate in cases of therapy cessation. 15, 26 In the last few years, basal serum HBsAg quantification and on-treatment kinetics have been proposed as surrogate markers for treatment outcome prediction in patients treated with PEG-IFN. [27] [28] [29] Interestingly, guidelines for avoiding risks resulting from discontinuation of NA have been recently proposed and incorporated in the official JSH guidelines for the management of HBV infection. 22, 23 Such recommendations are based on a score that includes HBsAg and HBcrAg levels for NA therapy cessation in CHB patients with at least 2 years of NA treatment, with undetectable HBV DNA and negative serum HBeAg. 23 Accordingly, patients with HBsAg load <1.9 Log IU/mL and HBcrAg <3.0 Log U/mL have a low risk of relapse (predicted success rate 80-90%) whereas patients with HBsAg >2.9 Log IU/mL and HBcrAg >4.0 Log U/mL must continue treatment (predicted success rate 10-20%). 23 In the present study investigating hepatitis B e-minus patients, we found that HBcrAg levels were moderately correlated with HBV DNA with a significantly higher correlation coefficient in PEG-IFN-α-treated patients compared to those treated with NA (P = 0.0077). However, the same analysis on only pretreatment serum samples should no significant differences (P = 0.4303). Therefore, the different mechanism of action of the two classes of drugs may explain these findings. Likely, NA exerts a higher impact on viral replication than on core-related protein production. Conversely, no correlation was found between HBcrAg and HBsAg, which is in contrast to a recent study by Maasoumy and colleagues using 249 blood samples of European untreated HBsAg-positive patients chronically infected with HBV genotype A/D. 19 The smaller study cohort and the impact of therapy could explain the different results. In our study, we found that treatment affected HBcrAg more than HBsAg kinetics, probably explaining the weak correlation between these two markers.
Among patients treated with PEG-IFN-α, we found higher baseline HBcrAg levels in non-responder patients compared to relapsers (P = 0.0458) in spite of no difference in HBV DNA and HBsAg pretreatment levels. Because of the low number of patients treated with PEG-IFN-α and the absence of patients who achieved a sustained response, it was not possible to carry out any statistical analyses to investigate the role of basal HBcrAg levels in such patients. Of note, recent reports suggest that a rapid on-treatment HBcrAg level decline predicts response to IFN-based therapy in both HBeAg-positive and -negative patients. 30, 31 To our knowledge, no studies have evaluated HBcrAg kinetics compared to HBV DNA and HBsAg in a cohort of HBeAg-negative CHB genotype D patients treated with NA or PEG-IFN-α. Interestingly, in NA-treated patients, we identified a subgroup with lower basal HBcrAg levels (3.8 ± 1.7 Log U/mL) who experienced a rapid decline to <2 Log U/mL within the first year of treatment, and a subgroup with higher basal HBcrAg levels (5.9 ± 1.3 Log U/mL) with still detectable HBcrAg after 3 years of treatment. The two subgroups were similar for HBV DNA and HBsAg basal levels and kinetics. Recently, Jung and colleagues showed that HBcrAg levels could be a useful marker to identify HBeAg-negative patients who are at risk of hepatitis reactivation after LAM or ETV therapy cessation. 32 Indeed, the authors found that age >40 years (odds ratio 6.690; 95%CI, 1.314-34.057; P = 0.022) and end-oftreatment HBcrAg level > 3.7 Log U/mL (odd ratio 3.751; 95%CI, 1.187-11.856; P = 0.024) were significantly and independently associated with virological relapse. 32 Similarly, Matsumoto and colleagues previously reported that HBcrAg levels were significantly higher in patients who experienced hepatitis reactivation after LAM discontinuation (4.9 [4.7-4.9] Log U/mL vs. 3.2 [< 3.0-4.5] Log U/mL, P = 0.009). 15 In the present study, we did not aim at evaluating the role of HBcrAg in predicting durable offtreatment response after NA treatment cessation. However, our findings are consistent with the classification obtained from application of the scoring system for risk of relapse suggested by the JSH guidelines. 23 In fact, we found that patients still positive for HBcrAg at month 36 had a significantly higher risk of relapse score compared to rapid HBcrAg decliner patients (P = 0.0005). This observation suggests a potential clinical role for HBcrAg kinetics in patients chronically infected with hepatitis B genotype D virus under NA treatment. Nevertheless, NA cessation may not be advisable in patients with cirrhosis for the risk of decompensation.
Finally, it has been reported that HBcrAg is able to reflect viral replication and, much more importantly, intrahepatic HBV cccDNA levels. 11 This aspect is particularly relevant in patients undergoing NA therapy as HBV protein production depends on the transcription of mRNA from cccDNA that is unaffected by NA treatment. In addition, HBeAg and core protein production requires the entire HBV cccDNA, whereas HBsAg can be synthesized either from cccDNA or HBV DNA fragments integrated into the host genome. 33 Therefore, we can cautiously speculate that HBcrAg measurement may represent a reliable surrogate marker for intrahepatic cccDNA evaluation.
The major limitations of our research are represented by the retrospective nature of the study and the low number of included patients. Scientific reports for longitudinal data come mainly from studies involving Asian patients infected with HBV genotypes B/C. Here, we provide data on the correlation and kinetics of HBV markers in a cohort of HBeAg-negative CHB genotype D patients treated either with NA or PEG-IFN-α.
In conclusion, we found a positive correlation between serum HBcrAg and HBV DNA levels, particularly in PEG-IFN-α treated patients, most likely due to expression of viral replication activity. In NA-treated patients, we observed two distinct patterns of HBcrAg kinetic, suggesting different relapse risk in cases of NA cessation. As consensus criteria for stopping NA treatment are still lacking, particularly in CHB genotype D patients, further studies are needed to elucidate whether these two patterns are consistent and, accordingly, if HBcrAg may represent a marker for safe discontinuation of NA therapy in such patients.
